SNWV at a glance
SANUWAVE Health, Inc. (SNWV, SEC CIK 1417663) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 25, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), SANUWAVE Health, Inc. (SNWV) reported revenue of $44.1 million (up 35.0% from FY2024) and net income of $11.8 million. Diluted EPS was $0.41.
- As of June 30, 2026, 14 institutional investment managers tracked by SignalX reported holding SANUWAVE Health, Inc. (SNWV) shares worth $7.9 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $44.1M
- +35.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 14 funds
- $7.9M · −2 vs prior quarter
- Latest 8-K
- Sep 25, 2026
- Item 3.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $9.739M, down 3% YoY from $10.054M
- Gross margin 76% vs 78% YoY; operating loss $0.280M vs income $1.438M
- Consumables revenue $7.3M, up 12%; UltraMIST® systems $2.3M, down 34%
- Cash $9.4M; operating cash flow $0.822M vs use of $0.524M YoY
- $2.9M term-loan principal payments; weaker capital sales and elevated inflation headwinds
Risk Factors
- Equity issuance risk: 4,000 common shares issued to Big Vision Ventures LLC as consultant compensation
- Securities-law compliance risk: reliance on Securities Act Section 4(a)(2) registration exemption
AI summary of the SNWV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- Nasdaq MVLS below $50 million for 30 consecutive business days, triggering a continued-listing deficiency
- Common stock remains listed on Nasdaq Global Market with no immediate delisting
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results released for quarter ended June 30, 2026
- Investor conference call scheduled August 7, 2026 at 8:30 a.m. EST
Item EX-99.1: Item EX-99.1
- Q2 revenue $9.7M, down 3%; gross margin fell to 76.2% from 78.1%
- Ultramist systems sold declined to 82 from 116, while applicator revenue rose 13% to $7.3M
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 section contains only incorporation-by-reference disclaimer language
- No earnings figures, reporting-period results, or operating metrics provided
Item EX-99.1: Item EX-99.1
- Preliminary Q2 2026 revenue $9.6–$9.8M, exceeding revised guidance ceiling of $9.5M
- Revenue down approximately 3–5% from $10.1M in Q2 2025, signaling continued capital-sales pressure
AI summaries of SNWV 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SNWV
Don't miss the next SNWV filing
- Alerts as it files. A push when SNWV files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SNWV, by share count.
- Ask anything. An AI agent that reads every SNWV filing and answers with sources.
SNWV alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Miller Ian D. | A | Sep 30, 2026 | 12,697 | - |
| Bazar Gregory Matthew | A | Sep 30, 2026 | 11,286 | - |
| Tyler James | A | Sep 30, 2026 | 11,286 | - |
| FRANK MORGAN C. | A | Sep 30, 2026 | 11,286 | - |
| Blizard Jeffrey | A | Sep 30, 2026 | 11,286 | - |
| Bazar Gregory Matthew | A | Jun 30, 2026 | 5,524 | - |
| Blizard Jeffrey | A | Jun 30, 2026 | 5,524 | - |
| Tyler James | A | Jun 30, 2026 | 5,524 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $32.6M | $44.1M |
| Gross Profit | - | $24.6M | $34.0M |
| Operating Income | - | $5.4M | $4.9M |
| Net Income | - | -$31.4M | $11.8M |
| Gross Margin | - | 75.2% | 77.1% |
| Op. Margin | - | 16.6% | 11.2% |
| Net Margin | - | -96.1% | 26.8% |
| Balance Sheet | |||
| Total Assets | - | $30.1M | $37.3M |
| Equity | -$44.5M | -$12.7M | $1.6M |
| ROE | - | 246.7% | 729.6% |
| Per Share | |||
| EPS | - | $-7.03 | $0.41 |
| Cash Flow | |||
| Operating CF | - | $2.5M | $3.9M |
| CapEx | $0 | $490K | $1.9M |
Source: XBRL data in SANUWAVE Health, Inc. (SNWV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate SNWV share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 14 | $7.9M |
| Q1 2026 | 16 | $21.0M |
| Q4 2025 | 14 | $36.8M |
| Q3 2025 | 14 | $46.9M |
| Q2 2025 | 13 | $33.2M |
| Q1 2025 | 6 | $10.9M |
- Citadel Advisors LLC+41.4K (+229%)
- JPMorgan Chase & Co+36.6K (+1202%)
- Morgan Stanley+25.8K (+446%)
- Vanguard Capital Management LLC+3.9K (+1%)
- FMR LLC (Fidelity)+3.3K (+284%)
- BlackRock−321.7K (-67%)
- State Street Corp−107.8K (-77%)
- Northern Trust−46.3K (-74%)
- Millennium Management−7.7K (-31%)
- Bank of America Corp−6.9K (-27%)
- Vanguard Portfolio Management LLC−44.3K
- BNY Mellon−15.8K
- Wells Fargo & Co−2.7K
- Citigroup−390
Source: 13F-HR filings on SEC EDGAR (aggregated from 77 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SNWV filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 8-K | Sep 25, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Jul 13, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 8-K | Jun 15, 2026 | - | Analysis | - |
| 8-K | May 12, 2026 | - | Analysis | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 4 | May 4, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 21, 2026 | - | - | - |
| 8-K | Apr 16, 2026 | - | Analysis | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
SNWV SEC filings: frequently asked questions
Which institutions hold SNWV stock?
As of June 30, 2026, the largest SANUWAVE Health, Inc. (SNWV) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($3.5 million), BlackRock ($1.6 million), Citadel Advisors LLC ($595,000), Goldman Sachs Group ($405,000), JPMorgan Chase & Co ($391,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SNWV's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), SANUWAVE Health, Inc. (SNWV) reported revenue of $44.1 million (up 35.0% from FY2024) and net income of $11.8 million. Diluted EPS was $0.41. The figures come from the XBRL data in the 10-K.
What did SNWV report in its latest 8-K?
SANUWAVE Health, Inc. (SNWV) filed an 8-K on September 25, 2026 reporting Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule). Nasdaq MVLS below $50 million for 30 consecutive business days, triggering a continued-listing deficiency.
What are the latest SNWV SEC filings?
SANUWAVE Health, Inc. (SNWV) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 25, 2026 and a Form 4 insider filing on October 2, 2026.
What is SNWV's SEC CIK number?
SANUWAVE Health, Inc. (SNWV)'s SEC Central Index Key (CIK) is 1417663. EDGAR lists every SNWV filing under that number.
Ask anything about SNWV
The research agent reads SNWV's filings, financials, insider trades and 13F holders, then answers with sources.